Phosphatidylserine targeting antibody in combination with anti-PD-1 antibody treatment activates infiltrating T lymphocytes of the spleen and tumor microenvironment in pre-clinical models of melanoma and breast cancer.

被引：0
|
作者：
Huang, Xianming
Gong, Jian
Van Nguyen
Yin, Shen
Baldwin, Carrie
Brekken, Rolf A.
King, Steven
Hutchins, Jeff
Freimark, Bruce
机构：
[1] Univ Texas Southwestern, Dallas, TX USA
[2] Peregrine Pharmaceut Inc, Tustin, CA USA
[3] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3059
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3059
引用
收藏
页数：1
相关论文
共 34 条
  • [1] Phosphatidylserine-targeting antibody synergizes with anti-PD-1 antibody to inhibit tumor growth in K1735 mouse melanoma model
    Huang, Xianming
    Ye, Dan
    Brekken, Rolf
    Yin, Yi
    CANCER RESEARCH, 2014, 74 (19)
  • [2] The relationship between tumor-infiltrating lymphocytes, PD-L1 expression, and clinical outcomes of Asian melanoma patients treated with anti-PD-1 antibody.
    Lee, Soo Jung
    Chae, Yee Soo
    Kim, Jong Gwang
    Kang, Byung Woog
    Baek, Jin Ho
    Choi, Hyeokjin
    Lee, In Hee
    Jeong, Ji Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] 89Zr-labeled anti-PD-1 antibody for in vivo monitoring of infiltrating PD-1+ T lymphocytes in a pancreatic tumor mouse model
    Liu, Liang
    Geller, Anne
    Yan, Jun
    Guo, Haixun
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [4] A combination treatment with a water extract from Euglena gracilis and anti-PD-1 antibody strongly inhibits growth of lung cancer in mice through stimulating tumor-infiltrating lymphocytes
    Ishiguro, Susumu
    Devader, Sarah
    Blake, Caden
    Glover, Logan
    Upreti, Deepa
    Nakashima, Ayaka
    Suzuki, Kengo
    Comer, Jeffrey
    Tamura, Masaaki
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 147
  • [5] Efficacy of Anti-PD-1/PD-L1 Monoclonal Antibody Treatment of Advanced NSCLC on Density and Distribution of Tumor Infiltrating T Cells
    Wang, Y.
    Wo, Y.
    Xue, X.
    Xue, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S333 - S333
  • [6] Selinexor synergizes with anti-PD-1 antibody and inhibits tumor growth and metastasis in syngeneic mouse models of KRAS mutant colorectal cancer.
    Chang, Hua
    Henegar, Leah
    Walker, Christopher J.
    Kashyap, Trinayan
    Maloof, Marie
    Wang, Feng
    Martyn, Kathleen
    Orr, Shira
    Kauffman, Michael G.
    Shacham, Sharon
    Landesman, Yosef
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Anti-PD-L1 antibody biodistribution, imaging and dosimetry in a pre-clinical breast cancer model: prospects for combination immune checkpoint inhibition and radiopharmaceutical therapy
    Josefsson, Anders
    Park, Sunju
    Jammes, Fabien
    Ray, Sangeeta
    Sgouros, George
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [8] Intratumoral plasmid IL-12 enhanced the systemic anti-tumor effect of anti-PD-1 antibody in triple-negative breast cancer.
    Nagata, Hiroshi
    Osada, Takuya
    Crosby, Erika J.
    Canton, David A.
    Twitty, Chris G.
    Lyerly, H. Kim
    CANCER RESEARCH, 2021, 81 (13)
  • [9] Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
    Kato, Yu
    Tabata, Kimiyo
    Kimura, Takayuki
    Yachie-Kinoshita, Ayako
    Ozawa, Yoichi
    Yamada, Kazuhiko
    Ito, Junichi
    Tachino, Sho
    Hori, Yusaku
    Matsuki, Masahiro
    Matsuoka, Yukiko
    Ghosh, Samik
    Kitano, Hiroaki
    Nomoto, Kenichi
    Matsui, Junji
    Funahashi, Yasuhiro
    PLOS ONE, 2019, 14 (02):
  • [10] High affinity and potent anti-tumor efficacy of Nivo813, an anti-PD-1/ALK-1 bispecific antibody, in pre-clinical studies for solid tumors
    Zhou, Qingqing
    Tang, Rong
    Zhuang, Lanfang
    Huang, Jianyu
    Qian, Jiang
    Ren, Zhihua
    Tong, Youzhi
    CANCER RESEARCH, 2024, 84 (06)
1234